The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. BridgeBio Pharma Inc shares valued at $2,504,978 were sold by Kumar Neil on May 20 ’25. At $33.40 per share, Kumar Neil sold 75,000 shares. The insider’s holdings dropped to 4,798,447 shares worth approximately $157.58 million following the completion of this transaction.
Also, Kumar Neil sold 26,156 shares, netting a total of over 871,764 in proceeds. Following the sale of shares at $33.33 each, the insider now holds 217,404 shares.
Before that, NEIL KUMAR had added 26,156 shares to its account. In a trade valued at $885,119, the Director bought BridgeBio Pharma Inc shares for $33.84 each.
As published in their initiating research note from Redburn Atlantic on March 31, 2025, BridgeBio Pharma Inc [BBIO] has been a Buy and the price target has been revised to $50. Analysts at Scotiabank started covering the stock with ‘”a Sector outperform”‘ outlook in a report released in mid October. As of October 03, 2024, Oppenheimer has initiated its “Perform” rating for BBIO. Earlier on September 04, 2024, Piper Sandler initiated its rating. Their recommendation was “an Overweight” for BBIO stock.
Analyzing BBIO Stock Performance
During the last five days, there has been a drop of approximately -2.44%. Over the course of the year, BridgeBio Pharma Inc shares have jumped approximately 19.68%. Shares of the company reached a 52-week high of $39.54 on 04/30/25 and a 52-week low of $27.53 on 01/02/25.
Support And Resistance Levels for BridgeBio Pharma Inc (BBIO)
According to the 24-hour chart, there is a support level at 32.34, which, if violated, would cause prices to drop to 31.84. In the upper region, resistance lies at 33.51. The next price resistance is at 34.18. RSI (Relative Strength Index) is 40.41 on the 14-day chart, showing neutral technical sentiment.
